CSPC Pharmaceutical Group Limited (FRA:CVG)
Germany
· Delayed Price · Currency is EUR 0.8156
-0.0060 (-0.73%)
At close: Jun 20, 2025, 10:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2018 - 2020 |
Vitamin C | 2.12B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Growth | 13.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics | 1.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Growth | -5.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others | 1.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Growth | -19.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nervous System | 8.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nervous System Growth | -8.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 3.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | -47.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Anti-Infectives | 3.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Anti-Infectives Growth | -16.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular | 1.77B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Growth | -31.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory System | 1.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Respiratory System Growth | -30.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Digestion and Metabolism | 1.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Digestion and Metabolism Growth | 2.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Therapeutic Areas | 1.23B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Therapeutic Areas Growth | -7.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Licence Fee Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Licence Fee Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2018 - 2020 |
Finished Drugs Segment Profit | 4.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Finished Drugs Segment Profit Growth | -37.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Segment Profit | 297.18M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vitamin C Segment Profit Growth | -2239.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Segment Profit | 284.28M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Antibiotics Segment Profit Growth | 21.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Segment Profit | 265.59M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Functional Food and Others Segment Profit Growth | -50.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | -337.15M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | -22.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2017 - 2019 |
Mainland China |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Mainland China Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Asian Regions |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Asian Regions Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Americas Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Revenue (Pre-FY2023 Reporting) |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Revenue (Pre-FY2023 Reporting) Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|